188 related articles for article (PubMed ID: 37849819)
1. Severe thyrotoxicosis induced by tislelizumab: a case report and literature review.
Huo L; Wang C; Ding H; Shi X; Shan B; Zhou R; Liang P; Hou J
Front Oncol; 2023; 13():1190491. PubMed ID: 37849819
[TBL] [Abstract][Full Text] [Related]
2. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
3. Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review.
Bai J; Li D; Yang P; Xu K; Wang Y; Li Q; Liu J; Du W; Zhang F; Feng R
Front Oncol; 2021; 11():778185. PubMed ID: 35047395
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
5. Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review.
Wang S; Peng D; Zhu H; Min W; Xue M; Wu R; Shao Y; Pan L; Zhu M
Front Oncol; 2022; 12():1053370. PubMed ID: 36568231
[TBL] [Abstract][Full Text] [Related]
6. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
7. Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: a case report and literature review.
Wei H; Zuo A; Chen J; Zheng C; Li T; Yu H; Guo Y
Front Immunol; 2023; 14():1295310. PubMed ID: 38292481
[TBL] [Abstract][Full Text] [Related]
8. Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study.
Ueba Y; Yamauchi I; Hakata T; Fujita H; Okamoto K; Ikeda K; Ueda Y; Fujii T; Taura D; Inagaki N
Endocr J; 2023 Mar; 70(3):323-332. PubMed ID: 36464271
[TBL] [Abstract][Full Text] [Related]
9. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.
Muir CA; Wood CCG; Clifton-Bligh RJ; Long GV; Scolyer RA; Carlino MS; Menzies AM; Tsang VHM
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1843-e1849. PubMed ID: 35104870
[TBL] [Abstract][Full Text] [Related]
10. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland.
Yamauchi I; Hakata T; Sugawa T; Kosugi D; Fujita H; Okamoto K; Ueda Y; Fujii T; Taura D; Harada N; Inagaki N
Endocr J; 2023 Oct; 70(10):987-998. PubMed ID: 37574279
[TBL] [Abstract][Full Text] [Related]
11. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
13. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
14. Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature.
Zhou Q; Qin Z; Yan P; Wang Q; Qu J; Chen Y
Front Immunol; 2023; 14():1226993. PubMed ID: 37869004
[TBL] [Abstract][Full Text] [Related]
15. Thyrotoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma.
Ariyasu H; Inaba H; Ota T; Yamaoka H; Furukawa Y; Iwakura H; Doi N; Yamamoto Y; Akamizu T
In Vivo; 2018; 32(2):345-351. PubMed ID: 29475919
[TBL] [Abstract][Full Text] [Related]
16. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
19. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
20. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
